Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (“Satellos” or the “Company”), a public biotech company developing new small molecule therapeutic a

Stock Titan provides an ultra-fast stock market news feed and multiple tools for traders and investors.

Satellos Bioscience earns FDA Fast Track for SAT-3247 in Duchenne, completing a triple designation. Trinity Biotech publishes 5,000 hours of CGM+ pre-pivotal wear data on false-low glucose detection. ...

Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (“Satellos” or the “Company”), a public biotech company developing new small molecule therapeutic a

Leede analyst Doug Loe has reiterated a “Speculative Buy” rating on Toronto-based Satellos Bioscience Leede analyst Doug Loe reiterated a “Speculative Buy” rating on Toronto-based Satellos Bioscience (Satellos Bioscience Stock Quote, Chart, News, Analysts, Financials TSX:MSCL) in a Feb. 9 update and revised his one-year price target to US$16.00, reflecting the company’s recently completed share consolidation and equity financing, while leaving his core clinical thesis unchanged.

Satellos’ DMD treatment shows efficacy signals in adult patients  Clinical Trials Arena

Satellos Bioscience Inc. (TSX: MSCL, OTCQB: MSCLF) (“Satellos” or the “Company”), a public biotech company developing new small molecule therapeutic a

Toronto, Wednesday, 11 December 2024.Satellos Bioscience has dosed the first participant in their Phase 1B trial of SAT-3247, marking a key step in developing treatments for Duchenne Muscular Dystroph

Satellos Bioscience Inc. has announced encouraging data from the company’s Phase 1b open-label study of SAT-3247, an oral small molecule inhibitor of AAK, designed to address progressive muscle loss by restoring muscle regeneration in response...

Wildon Farwell, MD, CMO at Satellos, discusses the safety and efficacy of SAT-3247, a new treatment option for Duchenne muscular dystrophy.